Hormone Related Cancer Mechanistic and Nanomedicines

Chapter 1. Conventional Treatment Approaches in Hormonal Cancer Treatment and Challenges.- Chapter 2. Concept of Nanomedicine in Endocrine Hormone Cancer Treatment.- Chapter 3. Progress of Cancer Nanomedicine, Clinical Hurdles and Opportunities.- Chapter 4. Emergence of Nanohybrids in Hormonal Cancer Targeted Therapy.- Chapter 5. Conventional to Nanoscale-Based Carrier System in Management of Ovarian Cancer.- Chapter 6. Pancreatic Cancer Nanoparticles Targeted Therapy via Epidermal Growth Factor Receptor.- Chapter 7. Nanocarriers Based Targeted Therapies for Pancreatic Cancer and Challenges Ahead.- Chapter 8. Pancreatic Cancer Treatment by Using of Theranostics Nanoparticles.- Chapter 9. Nanomedicine Based Combinational Therapy for Breast Cancer.- Chapter 10. Nano-Liposomal System for Breast Cancer Therapy.- Chapter 11. Conventional to Nanotherapeutic Strategies against Triple-Negative Breast Cancer.- Chapter 12. Effect of Thymoquinone and Its Delivery Through Using of Nanomedicine inBenign Prostatic Hyperplasia.- Chapter 13. Concept of Nanotechnology in Management of Neuroendocrine Tumours.- Chapter 14. Neurocognitive Underpinning of Neurological Disorders: The Role of Default Mode Network.- Chapter 15. Neuroendocrine Carcinoma of The Endometrium: Conventional Treatment Approach to Nanomedicine.- Chapter 16. Effective Luteinizing Hormone Drug Delivery by Gold Nanoparticles in Hormonal Cancer Treatment.- Chapter 17. Regulatory Landscapes in Approval of Cancer Vaccines.

Mahfoozur Rahman, Ph.D. is serving as Assistant Professor at the Department of Pharmaceutical Sciences, Faculty of Health Science, Sam Higginbottom University of Agriculture, Technology & Sciences (SHUATS), Allahabad, India. His major areas of research interest include development and characterization of nanosized drug delivery systems for cancer and inflammatory disorders including psoriasis, arthritis, and neurodegenerative disorders, etc. To date, he has published over 150 publications in peer-reviewed journals, 50 book chapters, 07 International books, and 04 articles in international magazine. He has Google Scholar H-index of 32 and over 3200 citations to his credit. Dr Rahman also served as Guest Editor of several journals including Seminar in cancer Biology. Besides, Dr Rahman got travel grant from various international congress such as IAPRD, MDS, Nano Today Conference, KSN, WCN, on the basis of his research work and contribution in thefield.



Waleed Hassan Almalki, PhD, is a Professor of Pharmacology at the College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia. He earned his doctoral degree at the University of Glasgow, United Kingdom, having a dissertation on ocular pharmacology. His current research is focused on the broad areas of host-virus networks in hepacivirus C disease progression as well as host- virus genes expression during oxidative stress, hepatic steatosis, fibrosis, and hepatocellular carcinoma. He is also enthusiastically involved in the studies of tyrosine kinase inhibitors for the treatment of breast and colon cancer, in the Saudi population. Dr. Almalki has published many research and review articles in peer-reviewed international journals on HCV pathogenesis, treatment, and drug designing, as well as edited various book chapters about angiogenesis, pharmacological assays, and infectious disease epidemiology.



Majed Al Robaian, Ph.D., Dean, Faculty of